Clinical Trial

Linperlisib Combination With Obinutuzumab Frontline Treatment of Marginal Zone Lymphoma Patients (MZL)

Study acronym: MZL-001
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated September 19, 2024 (before its estimated August 13, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a single arm, open label, national multicenter clinical study included patients with marginal zone lymphoma patients (MZL) , aim is to evaluate the efficacy and safety of first-line treatment with Linperlisib combined with obinutuzumab in patients with marginal zone lymphoma (MZL).
Trial Details
NCT Number NCT06592170
Lead Sponsor The First Hospital of Jilin University
Conditions Lymphoma
Enrollment 35 participants
Start Date 2024-08-13
Primary Completion 2025-08-13 (estimated)
Study Completion 2027-08-13 (estimated)
Updated on ClinicalTrials.gov 2024-09-19